Free Trial

Generation Bio (GBIO) Competitors

-0.07 (-2.50%)
(As of 07/12/2024 ET)


Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include NGM Biopharmaceuticals (NGM), Mersana Therapeutics (MRSN), Revance Therapeutics (RVNC), Editas Medicine (EDIT), SIGA Technologies (SIGA), Pharming Group (PHAR), PepGen (PEPG), Silence Therapeutics (SLN), Corbus Pharmaceuticals (CRBP), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "medical" sector.

Generation Bio vs.

NGM Biopharmaceuticals (NASDAQ:NGM) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.

75.7% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Generation Bio shares are held by institutional investors. 35.9% of NGM Biopharmaceuticals shares are held by company insiders. Comparatively, 21.1% of Generation Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Generation Bio had 5 more articles in the media than NGM Biopharmaceuticals. MarketBeat recorded 5 mentions for Generation Bio and 0 mentions for NGM Biopharmaceuticals. NGM Biopharmaceuticals' average media sentiment score of 0.74 beat Generation Bio's score of 0.00 indicating that Generation Bio is being referred to more favorably in the news media.

Company Overall Sentiment
NGM Biopharmaceuticals Neutral
Generation Bio Positive

Generation Bio has higher revenue and earnings than NGM Biopharmaceuticals. Generation Bio is trading at a lower price-to-earnings ratio than NGM Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$4.42M29.10-$142.38M-$1.72-0.90
Generation Bio$5.90M30.78-$126.61M-$2.55-1.07

NGM Biopharmaceuticals presently has a consensus price target of $2.53, indicating a potential upside of 63.96%. Generation Bio has a consensus price target of $8.00, indicating a potential upside of 193.04%. Given NGM Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Generation Bio is more favorable than NGM Biopharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NGM Biopharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
Generation Bio
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)

NGM Biopharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.83, meaning that its stock price is 183% more volatile than the S&P 500.

Generation Bio received 6 more outperform votes than NGM Biopharmaceuticals when rated by MarketBeat users. Likewise, 67.86% of users gave Generation Bio an outperform vote while only 60.38% of users gave NGM Biopharmaceuticals an outperform vote.

NGM BiopharmaceuticalsOutperform Votes
Underperform Votes
Generation BioOutperform Votes
Underperform Votes

Generation Bio has a net margin of -1,696.87% compared to Generation Bio's net margin of -3,223.34%. Generation Bio's return on equity of -77.85% beat NGM Biopharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NGM Biopharmaceuticals-3,223.34% -77.85% -67.76%
Generation Bio -1,696.87%-82.33%-46.73%


Generation Bio beats NGM Biopharmaceuticals on 14 of the 18 factors compared between the two stocks.

Get Generation Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GBIO vs. The Competition

MetricGeneration BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$181.63M$7.21B$5.27B$8.67B
Dividend YieldN/A2.79%2.84%4.09%
P/E Ratio-1.0721.19155.9718.27
Price / Sales30.78486.912,215.33109.19
Price / CashN/A32.5534.2432.05
Price / Book0.895.934.934.48
Net Income-$126.61M$146.83M$110.71M$215.59M
7 Day Performance26.39%10.50%6.13%5.39%
1 Month Performance-17.27%4.40%3.93%3.30%
1 Year Performance-60.43%-0.31%6.05%1.92%

Generation Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NGM Biopharmaceuticals
3.2264 of 5 stars
3.23 / 5 stars
Mersana Therapeutics
3.9126 of 5 stars
3.91 / 5 stars
-45.3%$223.92M$36.85M-1.61123Positive News
Gap Up
Revance Therapeutics
4.3265 of 5 stars
4.33 / 5 stars
-86.7%$278.88M$234.04M-0.74597News Coverage
Gap Up
Editas Medicine
4.7788 of 5 stars
4.78 / 5 stars
-38.9%$377.48M$78.12M-2.19265Short Interest ↓
Positive News
Gap Up
SIGA Technologies
0.1862 of 5 stars
0.19 / 5 stars
N/A+71.1%$550.47M$139.92M7.0445Options Volume
News Coverage
Pharming Group
2.6063 of 5 stars
2.61 / 5 stars
-28.9%$549.49M$245.32M-51.00382Short Interest ↓
News Coverage
Positive News
Gap Up
1.8246 of 5 stars
1.82 / 5 stars
+103.5%$545.95MN/A-5.1864Gap Up
Silence Therapeutics
2.0281 of 5 stars
2.03 / 5 stars
+262.5%$545.03M$31.55M-15.70109News Coverage
Corbus Pharmaceuticals
3.3093 of 5 stars
3.31 / 5 stars
+575.2%$537.66M$880,000.00-7.2319Analyst Forecast
Short Interest ↑
News Coverage
ORIC Pharmaceuticals
3.4739 of 5 stars
3.47 / 5 stars
+21.1%$518.46MN/A-4.27102Analyst Forecast
News Coverage

Related Companies and Tools

This page (NASDAQ:GBIO) was last updated on 7/12/2024 by Staff

From Our Partners